Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study

Man Fung Yuen, Sang Hoon Ahn, Kwan Sik Lee, Soon Ho Um, Mong Cho, Seung Kew Yoon, Jin Woo Lee, Neung Hwa Park, Young Oh Kweon, Joo Hyun Sohn, Jiyoon Lee, Jeong Ae Kim, Ching Lung Lai, Kwang Hyub Han

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)


Background & Aims We aimed to compare the viral suppression, safety and rate of drug resistance between besifovir (a new acyclic nucleotide analogue) and entecavir. Methods Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n = 31), 150 mg (n = 28) and entecavir 0.5 mg (n = 30) were monitored for liver biochemistry, viral serology, HBV DNA levels, development of drug resistance mutations, and adverse events throughout 96 weeks of treatment. Results The mean decline of HBV DNA levels from baseline to week 96 were 5.29, 5.15, and 5.67 logs IU/ml for patients receiving besifovir 90 mg, 150 mg and entecavir 0.5 mg, respectively (p >0.05). Undetectable HBV DNA (<20 IU/ml) were achieved in 80.7%, 78.6%, and 80%; ALT normalization in 90.3%, 78.6%, and 93.3%; and loss of HBeAg in 20%, 21.4%, and 22.2% of patients respectively (all p >0.05). One patient receiving besifovir 90 mg had a virological breakthrough due to drug non-compliance. No patient developed drug resistance mutations. Ten patients had serious adverse events, which were not related to the study medications. The most common side effect related to besifovir was carnitine depletion. Carnitine supplements were prescribed to 83.9% and 100% of patients, who had low carnitine level for any one time during follow-up, receiving besifovir 90 mg and 150 mg respectively. No patient had increased creatinine >0.5 mg/dl from baseline. Conclusions Besifovir had the same antiviral property as compared to entecavir over 96 weeks of treatment for chronic hepatitis B patients. Besifovir was well tolerated and also had a good clinical safety profile.

Original languageEnglish
Pages (from-to)526-532
Number of pages7
JournalJournal of Hepatology
Issue number3
Publication statusPublished - 2015 Mar 1
Externally publishedYes

Bibliographical note

Funding Information:
The present study was sponsored by LG Life Sciences, Ltd., South Korea .

Publisher Copyright:
© 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.


  • Besifovir
  • Entecavir
  • LB80380
  • Resistance
  • Safety
  • Viral suppression

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study'. Together they form a unique fingerprint.

Cite this